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Abstract
Background Patient-centered health care for children with in-
born errors of metabolism (IEM) and their families is impor-
tant and requires an understanding of patient experiences,
needs, and priorities. IEM-specific patient groups have
emerged as important voices within these rare disease com-
munities and are uniquely positioned to contribute to this un-
derstanding. We conducted qualitative interviews with IEM
patient group representatives to increase understanding of pa-
tient and family experiences, needs, and priorities and inform
patient-centered research and care.
Methods We developed a sampling frame of patient groups
representing IEM disease communities from Canada, the
United States, and United Kingdom. With consent, we
interviewed participants to explore their views on experiences,
needs, and outcomes that are most important to children with
IEM and their families. We analyzed the data using a qualita-
tive descriptive approach to identify key themes and sub-
themes.
Results We interviewed 18 organizational representatives be-
tween February 28 and September 17, 2014, representing 16
IEMs and/or disease categories. Twelve participants voluntar-
ily self-identified as parents and/or were themselves patients.
Three key themes emerged from the coded data: managing the
uncertainty associated with raising and caring for a child with a
rare disease; challenges associated with the affected child’s life
transitions, and; the collective struggle for improved outcomes
and interventions that rare disease communities navigate.
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Conclusion Health care providers can support children with
IEM and their families by acknowledging and reducing uncer-
tainty, supporting families through children’s life transitions,
and contributing to rare disease communities’ progress toward
improved interventions, experiences, and outcomes.
Background
Advances in diagnostic and therapeutic interventions for
children with inborn errors of metabolism (IEM) are
preserving and extending the lives of affected children.
However, the impacts of these interventions on the ex-
periences and daily lives of children with IEM and their
families are not well understood (Potter et al 2013).
While several studies have undertaken quantitative in-
vestigation into psychosocial, quality of life, and related
outcomes (Cederbaum et al 2001; Fabre et al 2013;
Weber et al 2012), fewer have described affected chil-
dren’s and families’ experiences using a qualitative ap-
proach (Packman et al 2010; Vegni et al 2010).
Nonetheless, the importance of understanding the patient
and family experience as part of providing patient-
centered care is gaining recognition (Liberati 2011).
This may be of particular importance for rare diseases
like IEM, where there is considerable clinical heteroge-
neity, emphasizing the relevance of personalized care
that is tailored to individual needs (Andersson et al
2005).
Patient groups have emerged as leading voices and advo-
cates for patients with rare diseases like IEM and their families
(Hall 2013). Often initiated by patients and families them-
selves, these groups have been instrumental toward defining
and furthering the needs and priorities of rare disease patient
communities (Dunkle et al 2010). The perspectives of these
groups thus promise to lend value to understanding the col-
lective experiences, priorities, and concerns of patients and
their families.
The Canadian Inherited Metabolic Diseases Research
Network (CIMDRN) is a national network of researchers
and collaborators investigating interventions and outcomes
for children with IEM and their families (Potter et al
2013). As part of CIMDRN’s research into patient and
family experiences, we conducted a qualitative interview
study to gain insight from patient groups that support
children with IEM and their families. Specifically, we
sought perspectives on some of the most important expe-
riences, needs, and priorities of families living with and
managing pediatric IEM. In addition to informing patient-
centered health care and support services for IEM, we
aimed to enrich and advance current understanding of chil-
dren’s and families’ experiences in order to support
patient- and family-oriented outcomes research in the field
of IEM.
Method
Design, sampling, recruitment, and participants
We sought to conduct qualitative, semi-structured interviews
with a maximum of 20–30 participants, or until saturation of
concepts and themes (Walker 2012) was reached. We devel-
oped a sampling frame of eligible patient groups using sug-
gestions from study investigators, the Canadian Directory of
Genetic Support Groups (Canadian Association of Genetic
Counsellors n.d.) and targeted internet searches. While eligi-
bility was initially limited to Canadian groups, it was later
expanded to include any English-speaking rare disease patient
group with a public Internet presence and a focus on one or
more IEMs. This expanded eligibility allowed for a larger
sampling frame from which to characterize experiences with
IEM—an objective that transcends geographic borders.
Individual participant eligibility was restricted to those
employed by, or working on a volunteer basis for, an eligible
group, and who held a spokesperson and/or representative
role. The particular eligible individual from the patient group
was generally selected by the respondent and/or the patient
group.
Recruitment invitations were distributed by email or web
contact forms in batches (between 5 and 21 at one time).
Eligible participants were invited to participate via e-mail or
electronic web forms available on the patient group internet
sites. Non-responders received one follow-up invitation.
Respondents were asked to provide signed, informed consent
to participate in the study and were provided with the pro-
posed interview questions in advance. Telephone interviews
were then scheduled, conducted, and audio-recorded. The
study protocol was approved by the Ottawa Health Science
Network Research Ethics Board (OHSN-REB).
Data collection
Interviews were conducted by two members of CIMDRN’s
research staff (SDK, KT) using a semi-structured interview
guide which was informed by a broad scoping review of rel-
evant patient- and family-oriented outcomes (Khangura et al
2015). The guide addressed such topics as quality of life,
physical, mental and social health, and health care experi-
ences. The guide was reviewed by study investigators with
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expertise in the clinical management of IEM and/or qualitative
research.
An experienced medical transcriptionist transcribed each
audio-recorded interview which was later verified by a
researcher (SS) who simultaneously listened to the audio-
recording while reading the corresponding transcript. In
one instance, the recording device failed; however, this
participant had provided unsolicited answers to the ques-
tions in the interview guide via e-mail prior to the inter-
view. Thus, we included data from this participant’s e-mail
answers.
Analysis
Given the overarching objectives of this study, the primary
analytical approach was qualitative descriptive (Sandelowski
2010). Thismethod is considered appropriate when describing
the ‘what’ of phenomena by minimizing interpretation
(Neergaard et al 2009; Sandelowski 2000).
Three researchers formed the core analytical team
(SDK, BKP, KT) and inductively identified initially broad
conceptual categories (sub-themes) using the first four in-
terview transcripts. Specific concepts were subsequently
identified, assigned codes, applied by one researcher
(SDK) using NVivo software (version 10), and reviewed
for credibility and trustworthiness (Shenton 2004) by a
second researcher (KT, SS). As the study progressed,
and interviews were transcribed and coded in parallel,
key themes emerged from the conceptual categories, which
were further explored in later interviews. Regular team
meetings were held to review findings as they emerged
and discuss the extent to which unique conceptual catego-
ries or themes were yet being identified, or whether satu-
ration had been reached (Walker 2012), informing deci-
sions concerning further recruitment.
Results
Participants
Forty-six recruitment invitations were distributed and 18
group representatives provided signed, informed consent, par-
ticipating in interviews between February 28, 2014, and
September 17, 2014, inclusive. Non-responders provided no
information about reasons for non-participation or -response.
Interviews ranged in duration from approximately 30 to
60 minutes.
Of the 18 respondents, five were male and most held var-
ious executive-level positions within their organizations, i.e.,
seven were President or Vice President; eight held
Directorship positions; and the remaining three were a Board
Member, Family Services Manager, and group Founder.
Diseases represented by participating patient groups were
as follows:
Box 1: Diseases represented by 18 participating IEM












rare diseases (answers specific to IEM were sought)
gaucher disease
inborn errors of metabolism (general)
phenylketonuria (PKU) (2)
Wilson disease
Twelve of the 18 participants provided estimates of
the number of children and families associated with
their group (the remaining six participants could not
provide an estimate), which ranged from two to 5000,
with a median of 100 children and their families per
group. This generally reflected the size of the group,
but also the degree to which the disease(s) were identi-
fied earlier versus later in life.
While the interviews sought information about affected
children and families associated with the group, 12 of the
participants self-identified as parents of affected children
and/or were themselves patients. Often, these participants
volunteered personal insights about living with an IEM. We
did not exclude these, nor distinguish between personally
lived experiences and perceptions about the experiences of
patients and families, as participants themselves did not draw
this distinction.
Prior to conduct of the last several interviews, satu-
ration of themes was suspected during a regular team
meeting at which the findings from the analyses were
assessed. This was confirmed at a follow-up meeting
after the 18th interview when the findings from the
analysis of the last several interviews were assessed.
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Recruitment was subsequently ended on September 17,
2014.
Child and family experiences with IEM: perspectives
of patient groups
Despite heterogeneity within and across diseases in the
patient group representatives’ perceptions about the ex-
periences and priorities of patients and their families,
we identified three key themes bearing relevance to
the full set of 18 interviews: coping with uncertainty
and the unknown; the challenges accompanying an af-
fected child’s major life transitions and; the collective
struggle for improved outcomes and interventions that
rare disease communities navigate. Sub-themes (based
on the conceptual categories in the coded data) were
also identified and are described as they appear within
the key themes.
Coping with uncertainty and the unknown
This theme emerged generally, as participants described the
daily lives and experiences of children and families (Box 2,
[1a–b]). Often, the unknown was associated with challenges
surrounding the diagnosis—generally a series of intense ex-
periences for families (Box 2, [2a]). Some participants
highlighted lengthy delays and/or misdiagnoses as acute ex-
acerbations of distress (Box 2, [2b]), or contributors to a cat-
astrophic outcome (Box 2, [2c]).
Following diagnosis, uncertainty about the child’s prog-
nosis and future was a common experience. For families
whose children had diseases with neurocognitive manifes-
tations, for example, challenges dealing with uncertainty
regarding how the child would be affected in the long-
term were described (Box 2, [3a]). In addition, for those
whose children had diseases that were progressive and
terminal, uncertainty about the child’s mortality was
highlighted (Box 2, [3b]).
Often, uncertainty was made manifest through interactions
with the health care system and health care providers. While
this was commonly described with respect to primary and
emergency care, even among specialist physicians, some par-
ticipants described perceived uncertainty (Box 2, [4a])—
reflecting the many remaining ‘unknowns’ about rare diseases
like IEM (Box 2, [4b]). Nonetheless, participants also
expressed recognition that health care providers cannot be
expected to have an in-depth understanding of all rare diseases
(Box 2, [4c]).
Some participants described strategies for managing uncer-
tainty and the unknown, including becoming self-informed
(Box 2 [5a]); gathering with other affected families for support
and information (Box 2, [5b]) and; educating others about the
disease (Box 2, [5c]).
Box 2: Coping with uncertainty and the unknown—
example quotes
Sub-theme 1: Dealing with the unknown (in general)
[1a] Participant (06): BI think for me [the most important impact on daily
life is] the unknown. Because like… you don’t know what the future’s
going to hold. That’s hard.^
[1b] Participant (12): BOne of the things that people find so difficult to
deal with is the uncertainty and the unknowing, sort of thing…^
Sub-theme 2: Uncertainty concerning diagnosis
[2a] Participant (03): BSo, you know there’s the challenges once you get
diagnosed, but there’s all those challenges before you were diagnosed,
and you know, often people go through a couple of years and several
specialists until they get the diagnosis.^
[2b] Participant (17): B… it’s my feeling that [the disease] is a very
under-diagnosed rare disease just because of the misdiagnosis for
5 years for my son… .. And there’s so many stories that are even worse
than that.^
[2c] Participant (05): B… quite often infants were actually diagnosed after
they had passed away… I can’t imagine being a parent who goes
through that.^
Sub-theme 3: Unknowns about the child’s prognosis and future
[3a] Participant (06): BI think just overall just the not knowing what
to expect and you’re hoping, you know, like I’m hoping my son
gets through high school. And I’m hoping he gets a diploma,
and if we can get him there I’ll be thrilled, you know. I’m not
looking at college, I’m not looking at university or anything for
him, but I’m hoping that maybe he can be responsible enough
that he can do something. Maybe in the trades, maybe with his
hands, and maybe we can set him up in his own business. So,
but that’s kind of a hard reality…^
[3b] Participant (16): BA lot of people want to know like, ‘When is,
you know, when is my child gonna die?’… Some doctors will
say, ‘Well you know, a kid with [the disease] is gonna die, you
know, between the ages of five and 10.’ So then like, every year you
know, the birthday is not something that is a happy celebration for
these families… [they] want to know ‘When is this gonna happen?’ And
just the unknowns about that.^
Sub-theme 4: Uncertainty among health care providers
[4a] Participant (10): BWell the primary care system has no idea… And
then even in the smaller clinics throughout the country, you know, they
may only have one patient with [the disease]. And so even though
they’re the specialists, they don’t know everything.^
[4b] Participant (01): BI think there’s a lot to be learned yet… there’s very
little research between symptoms—in general, between symptoms and
between [biochemical] levels.^
[4c] Participant (02): BI get it; there are 7000 rare diseases, and nobody
can be an expert on all of them.^
Sub-theme 5: Strategies for coping with the unknown
[5a] Participant (16): BIn most cases the families… very quickly become
the expert… I think just trying to understand the disease, becoming the
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expert and being able to advocate and share and raise awareness
about their disease locally is probably the hardest thing…^
[5b] Participant (01): BI mean at the best, the best we can do at our end is
to try to match families together so that they can share information and
you know talk to somebody who has the disorder and you know
understand what they do and how they cope.^
[5c] Participant (17): BI go in to my family doctor and whenever he’s got a
student in with him we sit down for 15 min and I educate him on [the
disease]… But this is part of raising awareness, ‘I’ll teach you about a
rare disease so that maybe 1 day in your life, if you come across these
symptoms you’ll remember’, right?^
Child’s life transitions
Experiences and challenges in the daily management of an
affected child’s health and well-being featured prominently
in the interviews—particularly those surrounding the
child’s life transitions. One of the first of these transitions
is entrusting the child’s care to others who may not fully
appreciate the gravity of the disease, often at the age
when the child begins daycare (Box 3, [1a]). Sometimes,
these challenges result in a change to the family dynamic,
as a parent may have to give up his or her career to
become a full-time caregiver (Box 3, [1b]).
Extending from this was the concept of introducing the
affected preschool child to the peer group. Depending on the
child and the disease’s manifestations, these were described
variably; one self-identified parent of a child with a disease
causing immunocompromise described organizing a low-
immunity playgroup at her local community center to support
her child’s socialization, and the emotional response from one
of the mothers in attendance (Box 3, [1c]).
As children transition to school, concerns around the trans-
fer of care, disease management, and social development con-
tinue (Box 3, [2a-b]). Likewise, depending on the manifesta-
tions of the disease, variable social and emotional challenges
were described (Box 3, [2c]).
During the adolescent transition, social challenges
were often described as being more acute; one self-
identified parent’s adolescent son with a progressive dis-
ease described the limitations imposed by the condition
and the challenges this introduces for sustaining long-
term, meaningful friendships (Box 3, [3a]). On the other
hand, adolescents with IEM for which self-management
must be actively adopted into adulthood face different
social challenges (Box 3, [3b]).
Finally, as adolescents ‘age out’ of pediatric health care,
they must navigate health systems that are often perceived as
being unprepared for managing those with IEMs who live as
long as many now do (Box 3, [3c]).
Box 3: Child’s life transitions—example quotes
Sub-theme 1: Early childcare and social development
[1a] Participant (08): B… when you’re also dealing with like daycare
providers—and they’ve got a lot of kids they’re dealing with—and how
do you make sure that your child is getting what he or she needs at the
daycare?^
[1b] Participant (15): BI know it’s something my family personally has
faced; the quandary of needing to work but not being able to because
of the severe needs, you know, the high needs and the maintenance
needed at home with the condition.^
[1c] Participant (07): BAnd this mum… came in crying… I said ‘You
know what, like, if this is causing you too much stress…that’s not
my intention’… she just kind of burst out crying and hugged me
and she said ‘Oh my god, no. I’m so happy,’ she said, ‘my daughter
is 4-and-a-half [years old] and this is the first time she’s ever been
with children’.^
Sub-theme 2: Transition to school
[2a] Participant (07): BYou know you’ve just got the daycare all on board
[with managing the disease], and you’re done daycare, and now you’re
going into the school system. It’s just over, and over, and over, and over
again.^
[2b] Participant (15): B…often [the symptoms] our children experience
are difficult for others to detect. So that’s always a concern for
parents, you know, in the school setting or any kind of setting
outside… especially when someone else is filling that caregiver
role you know either at school or the parents are at work and
things like that.^
[2c] Participant (06): B… he’ll [the participant’s affected son] come home
and he’ll say ‘Mummy, I just walked away from them [other children]
because, you know what? They’re not nice and I don’t need them as
friends’, you know… because his speech isn’t where it should be it
makes him very hard to understand and that causes a lot of social, you
know… no, not social issues; but he couldn’t express himself in the
beginning…^
Sub-theme 3: Transition through adolescence
[3a] Participant (12): BOne of [the participant’s son’s] big
challenges—and I think it is for a lot of the kids—is
socializing… [he] had a really close friend, but unfortunately
he moved away. And kids are really good with him, but no one
who’ll come over and play. I don’t blame them. I know back
when they were 9 or 10 they wanted to play baseball; [he’s]
not playing baseball. And they’re at the age where they talk
really quick and they do things really quick and [he’s] in a
wheelchair now and, you know. So, like I said they’re always
incredibly friendly but there’s nobody who would come over
and watch a movie with him.^
[3b] Participant (09): BI think the only adherence issues we see, as a rule,
tends to be at the moment of transition, and the young people being fed
up with being told what to do and saying that they’re going to make
their own decisions and not adhere to the diet or to the medication
because it’s their choice.^
[3c] Participant (13): B… you know a lot of the children… are now, as it
were, the oldest children who’ve ever lived with these conditions… So,
there’s no experience of how you provide services and support for
people in this position; essentially you’re making it up as you go
along…^
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Struggle for improved outcomes and interventions
A third, overarching theme was the collective struggle that
families living with IEM and their respective disease commu-
nities navigate in pursuit of improved interventions and out-
comes. While not always stated explicitly, this finding
emerged when considering the interviews in juxtaposition
with one another. For instance, the concept of access to health
care resources was described variably by different group rep-
resentatives, e.g., while some participants perceived their dis-
ease communities as having limited access and/or resources
(Box 4, [1a]), others described having celebrated important
progress in research and treatment availability (Box 4, [1b]).
Advances in communication—most notably internet and
social media—were often credited as an important driver of
progress in the struggle for information and interconnected-
ness. For example, information on the internet was sometimes
described as an important resource for the undiagnosed (Box
4, [2a]), or as means for empowering parents with information
about their child’s diagnosis (Box 4, [2b]). Most often, partic-
ipants credited internet and social media with providing im-
proved opportunities to connect with other affected families—
effectively reducing geographic distance as a communication
barrier and isolating factor (Box 4, [2c]). Though, while the
internet has brought progress, it was also acknowledged as a
potential source of misinformation (Box 4, [2d]).
Notably, information gathering using the internet was
linked to communication with health care providers (Box 4,
[3a])—an important part of achieving better outcomes. Some
participants described situations where parents necessarily be-
come ‘expert patients’ (by proxy) (Box 4, [3b]), while others
offered suggestions for improvements to communication be-
tween parents, health care providers, and health systems (Box
4, [3c]).
By extension, participants sometimes highlighted the need
for specific improvements in health services, such as better
care coordination to improve access, and even quality of life
(Box 4, [4a]). One self-identified parent described an inpatient
hospital experience during which her affected child was re-
peatedly moved from room to room, and the distress this
caused (Box 4, [4b]). This experience suggests that some im-
portant, patient-centered changes to health care delivery for
families living with IEMs and other rare diseases may be
neither complex nor expensive.
Concerning therapeutic interventions more specifically,
availability, management, and/or effectiveness were addressed
by all of the participants—often offering insight into progress
that has been made toward understanding and treating a par-
ticular disease. While some (though, few) participants report-
ed a perceived lack of interventions to treat the disease of
interest (Box 4, [5a]), those for whom specific treatments were
available sometimes described barriers to access and/or adher-
ence; these included costs, regulatory approvals and insurance
coverage (including variability across jurisdictions), side ef-
fects, and the rigour and/or intensity of the regimen (Box 4,
[5b–c]).
For those with access to treatments, challenges managing
the administration of these were commonly described; none-
theless, these challenges were consistently minimized along-
side gratitude for and/or the positive aspects of having treat-
ment available (Box 3, [5d]). As it concerned the concept of
treatment effectiveness, there was unsurprisingly wide varia-
tion with some treatments described as being minimally effec-
tive, while others were described as having apparent potential
for transformative effectiveness (though, not necessarily in all
patients) (Box 3, [5e]).
Box 4: Struggle toward improved outcomes and interven-
tions—example quotes
Sub-theme 1: IEM disease communities: challenges and successes
[1a] Participant (01): BSo the challenge for these people, first of all you
know, to get a diagnosis. Second of all, to get a physician who is
informed about it… the kind of questions we often get… are, ‘I have this
disorder’ or ‘I believe I have this disorder. I can’t get a physician to go
through the process of diagnosing it. Please help me find a physician.’
They almost always end with that, ‘please find a physician’. And you
know we’ve been working for over 2 years to try to get a tiny network of
physicians across [the country]who could provide some level of support.
And so at this point we have, I think, four who are aware. I think four or
five physicians that would see patients with [the disease].^
[1b] Participant (18): BSo yeah, I just think that right now the [disease
name] atmosphere is very, very positive and there’s a lot of support
from all the pharmaceutical companies that have treatments out there.
You know, we do our best to provide what we can as well, and doctors
are very giving of their time to patients so they don’t feel like they’re just
pushed through the system, yeah… So, I would, I’d probably say, it’s
probably more positive than negative out there! [laugh]^
Sub-theme 2: Role of the internet and social media
[2a] Participant (02): B… many of the adults that we know of diagnose
themselves from information on the internet, and went to the doctor
and said, ‘I think this is what I have.’^
[2b] Participant (16): BYeah, and things now with social media are so
different than they were… families that talk about ‘Well, when we got
the diagnosis, you know, we had to go to the library. You know, we
didn’t have Internet at home; we didn’t have a computer. You know, you
couldn’t Google it. You had to get this big medical textbook out.’ But
now families are going to Facebook and they’re finding families on
Facebook before they’re finding the [rare disease patient group].^
[2c] Participant (13): BIf you’ve got a condition which is a rare… you may
be the only patient for miles around who has that experience. But with,
you know, Facebook and things like that, you can be part of a group
which can have members all ‘round the world… it can help to reduce
the sense of isolation that comes for families who are dealing with
conditions which are poorly recognized and little understood.^
[2d] Participant (09): B… what we do find is sometimes that the
newspapers don’t do us any favours. And even the Facebook groups—
one person will claim that… their child’s had a treatment and it’s
wonderful and they’re cured and they’re so much better and they’re
going to school and they haven’t been to school for months. But we
know, sort of, from the outside, that that will only be a short-term thing
and that at some point they will be ill again.^
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Sub-theme 3: Importance of communication with clinicians
[3a] Participant (12): B… of course, with the electronic age there’s a
chance for parents to learn way more. You can read the journals, you
can hit all the updates and abstracts, etcetera, and you may not
necessarily understand it but you can write it down and then
regurg[itate]. Yeah, so I think parents can be fantastic resources, and I
think doctors… are very receptive to hearing from patients and you
know at least listening to it and going, ‘Okay, that makes sense’, or
‘No, that’s not [correct].’^
[3b] Participant (16): BI think just being able to admit when they don’t
know enough about this disorder, you know, because not all
physicians are willing to accept that usually the mum and dad
know more about this particular [disease]… it’s very common that
as a parent you are going to know more. You know, and to just be
able to willingly learn, you know, from the parent and listen to
them, because these kids with [the disease] don’t always present the
same way.^
[3c] Participant (03): B… electronic records aren’t really being used as
much as they should, or not at all in some places, and so you could
even be at that hospital a lot and they won’t even be able to pull up all
the information. So yeah, that’s an issue… people go in and they have
to explain the whole situation to people who really don’t understand
what they’re talking about.^
Sub-theme 4: Suggestions for improved health care
[4a] Participant (03): BAnd I mean, I think everybody who has a child with
a complex medical condition like this would benefit from having more
coordination. You know, being able to go into a clinic and see several
specialists in one day, for example those kinds of things. And that really
doesn’t happen right now. So, you know it’s a lot, and the burden of
getting to all these appointments is huge.^
[4b] Participant (06): B… like in a matter of three days that [hospital]
room had become my home, you know? And that was where I’d stay,
and I never left my son’s bedside. And then when they’d tell me we were
moving, like, my heart would just sink and I’d almost be in tears over it
because I couldn’t handle any more change… and that was very, very
difficult as a family… I know other parents have said the same thing
too…^
Sub-theme 5: Struggles and progress in treating the disease
[5a] Participant (01): BYes, well you know, there are no treatments. There
are some things that this particular family… already found, you know,
doesn’t help in their family. So there’s no treatment…^
[5b] Participant (04): BFor many families, access to treatments are a
struggle. Every [jurisdiction] is different but many patients do not
have access to the formulas… foods or medication that they need
to best manage [the disease] and minimize the neurocognitive
damage.^
[5c] Participant (13): BThen there’s the demands of the treatment
regime—where there is a treatment regime available. You know, a
lot of inborn errors of metabolism don’t yet have a therapy, but
hopefully will do as the process continues. And then there’s the
uncertainties about access which can produce stress and anxiety,
not just in the affected individual but also in the rest of the family.
So, you know you can imagine the situation: if you know there’s a
therapy coming through the licensing process, I mean, are you
going to be able to access it? And are you going to be able to
access it in a timely manner before your disease has progressed to
the point at which, you know, you are severely constrained in what
you can do?^
[5d] Participant (03): B… you know, some people travel to the hospital 3–
4 h each direction. I mean that happens, right? So, some people, that’s
taking 12–13 h; 14 h a week. So yeah, I mean, I would consider that
onerous. But the great thing is most people don’t really see it that way.
They’re grateful to have the option.^
[5e] Participant (16): B… it’s fascinating looking at those three [children],
you know—one who got the drug at two [years old], one who got the
drug at one [year old], one who got the drug at, like six weeks… A huge
major difference… of course, it’s so hard to demonstrate effectiveness
because of the small numbers of patients, and… how come the
treatment’s working on one kid and not in another? It’s just so hard,
right?^
Discussion
A rich variety of children’s and families’ experiences, needs,
and priorities were described by IEM patient group represen-
tatives withmany of the concepts being represented by the key
themes of coping with uncertainty, managing a child’s life
transitions, and the collective struggle for improved outcomes
and interventions.
Similar themes have emerged in the relatively scarce qual-
itative literature addressing patient and family experiences
with IEMs, such as Dimond’s study of adult patients with
mitochondrial disorders in which experiences that typify un-
certainty were highlighted (2013). Similarly, de Ru and col-
leagues describe the importance of a diagnosis in easing dis-
tress associatedwith the ‘unknown’ in parents of childrenwith
Mucopolysaccharidosis type I (MPS I) (2012). Likewise, an
accurate and timely diagnosis is documented elsewhere as an
important outcome for reducing the burden of uncertainty for
rare disease patients and families (Botkin et al 2010; Groft and
Posada de la Paz 2010). Thus, our findings support the notion
that achieving a diagnosis is itself a priority for patients and
families and thus is an important component of patient-
oriented care for rare diseases.
Our findings also suggest that patient self-organization is
important for both mitigating uncertainty and driving progress
toward improved treatments and outcomes for rare diseases.
While this finding is, at least in part, a function of our partic-
ipants’ roles within these groups, a growing literature exam-
ining rare disease patient self-organization reinforces it, sug-
gesting that patients and families are less isolated and more
empowered when they gather to share experiences and strate-
gies for overcoming challenges (Aymé et al 2008; Hall 2013).
Indeed, rare disease patient groups, social networks, and sup-
portive resources have been described as critically important
to the experiences of affected children and families and the
progress of rare disease communities (Humphreys 2012; New
York-Mid-Atlantic Consortium for Genetic and Newborn
Screening Services 2009). Notably, the role of for-profit in-
dustry in these activities should not be overlooked; rare dis-
ease patient groups often form strong relationships with the
well-financed pharmaceutical industry (Phillips 2013). To
moderate these relationships, there may be resource-efficient
ways that health care providers can support IEM patient
groups with less potential for conflicted interest.
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Finally, we identified challenges associated with supporting
an affected child through life transitions, consistent with other
studies: Ievers-Landis and colleagues report on adherence to
diet for phenylketonuria (PKU) patients as being particularly
problematic in adolescence (2005). Similarly, qualitative work
involving patients with PKU found that the social transitions
across the lifespan were particularly challenging for those af-
fected (Vegni et al 2010), and a study of children with
Niemann-Pick disease identified the ages of 10–16 as being
especially challenging socially (Henderson et al 2009). In addi-
tion, there is a growing literature addressing the transition of
adolescents from pediatric to adult health care (Gleeson and
Turner 2012; van Staa et al 2011; Zurynski and Elliott
2013)—some of which is specific to rare-diseases, including
IEM (Mutze et al 2011; Simoes et al 2014). Nonetheless, liter-
ature describing earlier life transitions, e.g., children entering
the educational system (Mescon and Honig 1995), seems to
have received less attention. Our findings highlight the need
for additional research addressing these earlier transitions, per-
haps focusing on synergies between health and educational
systems in supporting children with IEM and their families.
Strengths and limitations
One of the strengths of this study is its qualitative portrait of
child and family experiences frommany families living with a
wide variety of IEMs. However, this breadth of experiences
may come at the cost of depth, possibly overlooking unique,
and very important, concerns that one or more rare disease
communities may have.
The study’s breadth may have also introduced other limita-
tions, i.e., experiences living with IEM were sought via patient
organizations rather than from the families themselves. Since
many participants incorporated personal insights and experi-
ences alongside their perceptions of the experiences and prior-
ities of others, this limitation was mitigated to some extent.
Interviewing representatives of patient groups also brought a
unique perspective that included, for example, insights about
progress of entire rare disease communities. On the other hand,
the study’s findings do not differentiate subjective, lived expe-
riences from the objectively observed experiences of others.
Another potential limitation introduced by the study’s reli-
ance on patient group representatives is the absence of any
description of the experiences of those families for whom no
patient groups exist, or those who choose not to participate in
patient groups. While some reasons for group participation
were described by this study’s participants (i.e., information,
interconnectedness), it is not known why some families
choose to participate in IEM patient groups while others
choose to abstain from involvement. Studies examining rea-
sons for patient group participation in other disease commu-
nities suggest that positive attitude and perceived control may
be factors associated with patient group participation (Van
Uden-Kraan et al 2011; Voerman et al 2007). Nonetheless, it
must be acknowledged that any factors associated with non-
participation in IEM patient groups could also be associated
with unique experiences and priorities that were therefore not
captured by this study.
Conclusion
An improved understanding of the child and family experi-
ence living with IEM is an important part of ensuring that
health care and other social services are prepared to adequate-
ly support affected children and families. Participant sugges-
tions for improving care present an opportunity to consider
concrete ways of providing this support, e.g., improved coor-
dination of health care and a more collaborative, patient-
centered approach to communication between clinicians and
patients/families. Notably, some of these practical suggestions
may also be cost-effective.
Ultimately, recognition of the challenges associated with
uncertainty, managing a child’s transitions through life, and
the struggle for improved interventions and outcomes can help
health care providers consider other practical approaches to
supporting families living with IEM, as well. For instance,
clinicians can more intentionally recognize and work to reduce
the uncertainty that families struggle with by being transparent
in communicating what is and is not known and/or understood
about the disease and its treatment. Similarly, health care pro-
viders may be able to offer support to families by suggesting
coping strategies and resources for managing the child’s life
transitions. Finally, the health care provider may often have a
role to play in facilitating connections between families who
could benefit from the support of one another.
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